Personalized Tech designed to turn down pain
& turn up performance

Play Video

“Pain shouldn’t be chronic, and people shouldn’t have to live with it”


Things that differentiate Healables as a tech company





A company that strives to break decades of marginalization in the industry.

12 Reasons To Invest in Healables Now

Want to know what we think? Investing in Healables is a smart choice

1. Our Team

Moshe Lebowitz | CEO, Co-Founder

Moshe Lebowitz is a visionary who believes that humanity is on a positive trajectory and that we all have a responsibility to solve today’s biggest health challenges. He has previously served as UI/UX Designer, Product Manager and CEO. Lebowitz uses his rabbinic training to solve business problems differently and innovates through the creative integration of technology together with new inventions. Lebowitz practices Hasidic meditation and is trained in craniosacral therapy and Chinese medicine.


Dr. George Lowell | Chief Scientific Officer

Dr. George H. Lowell has served on both the Scientific Advisory Board and the Board of Directors of BiondVax. He was Chief Scientific Officer for BioDefense at GSK Biologicals. He retired from the US Army as a Colonel.  He has initiated numerous clinical studies and clinical trials for FDA Approval. His academic posts include Visiting Scientist at Weizmann and Visiting Professor, Hebrew University-Hadassah Medical Center. Dr. Lowell is an early angel investor in Healables and serves on the BoD.

Ellipse 23 (1)

Yehuda Barbasch | COO/CFO

Yehuda Barbasch has a background in international investment banking and has worked at Citibank and Pictet Wealth Management. His exceptional people skills, British accent and experience with all aspects of finance adds up to keen business planning and operational success. Yehuda holds a BBA in International Business from Leeds Beckett University and Aix-Marseille University and speaks English, French and Hebrew.

Ellipse 23 (2)

Dr. Andrew Shiller, MD| Chief Medical Officer

Dr. Andrew David Shiller, MD Chief Medical Officer. Dr. Shiller earned his MD at Duke University’s School of Medicine, continuing at Harvard Medical School, with double residency training in Internal Medicine & Physical Medicine & Rehab. He completed fellowship training in Integrative Medicine at University of Maryland Center for Complementary Medicine Research. He studied & practiced natural healing and stress-reduction, along with nutrition, hands-on healing, movement therapy & mind/body awareness.

Ellipse 23 (3)

Ziv Ritchie | BSEE – CTO

Ziv Ritchie trained in Electrical Engineering at the Jerusalem College of Technology. He studied Reality Therapy at the William Glasser Institute and helped Professor Joshua Ritchie, MD found and manage the Refuah Institute, the leading provider of Torah-based coach training in the world. Ziv combines his technological knowledge and development skills with his psychological training to develop the Healables digital health coaching app and oversee the development and production of Healables electroceutical devices and textiles.


Marco Van Der Putten Landau | CBDO

Marco van der Putten Landau is an international business development and marketing professional with the rare talent, ability and business acumen to add value and close deals by bringing people and businesses from all over the world together. Marco has lived in Europe, South America, China and Israel and is fluent in English, Spanish, French, Portuguese, Dutch, Italian and Chinese. Marco’s ability to understand and bridge cultural nuances empowers him to bring out the universal truths in the people that he works with and create business synergies and partnerships throughout the globe.


Yasha Harari | CMO

Yasha Harari is a marketing professional, having worked with a vast range of world class products and services. He has led marketing and driven record results for a variety of top B2B, B2C and B2B2C firms in the areas of medical devices, tech, gaming, FinTech, retail brands, trade associations, consumer goods, publishers, advertising companies, and many more, around the world. Yasha is responsible for pioneering significant Internet marketing gold standards used by people worldwide since decades.

2. Healables’ vision is to heal people with smart clothing instead of drugs.

Your dollars are not just going toward a financial investment. You’re investing in a company that strives to improve the quality of life of mankind. It’s like an ESG investment.

The Problem

Worldwide, chronic pain impacts over 770 million people.[4] In the US, the CDC reports that approximately 20% of adults suffer fromcolor: blue; various forms of chronic pain.[5] That’s an astonishing 51.6 million people![5a]

Current pain management options are often limited to:

Pain medication can have downsides such as addiction or other physical side-effects, which leaves a gap in treatment options.

The Center for Disease Control (CDC) recommends maximizing use of non-opioid therapies[6a]

The 2022 CDC Clinical Practice Guideline [6B]

The US Congress expands access to non-opioids

The NOPAIN Act[6c] was passed in an end-of-year legislative package in the 117th Congress in 2022. As a result of the law, patients and providers will have expanded access to non-opioids starting in 2025.
The Non-Opioids Prevent Addiction in the Nation Act (“NOPAIN Act”) is a policy that will prevent opioid addiction before it starts by increasing the use of non-opioid pain management approaches as a Medicare reimbursement policy in outpatient surgical settings.[11]
The NOPAIN Act will increase the use of non-opioid pain management approaches by changing outdated federal Medicare reimbursement policies.[6c][12] The policy will:

This NOPAIN Act will ensure that safe, non-addictive therapies are widely available to the tens of millions[6d] of Americans who undergo an outpatient surgical procedure every year. Drug-related overdoses and deaths were measurably accelerated[6e] during the COVID-19 pandemic resulting in the highest rates ever recorded. This policy change aims to reduce unnecessary exposure to opioids and the likelihood of opioid abuse or addiction following an acute pain incident.

3. Healables’ Solution
“Wearables that Heal”

Healables has developed novel wearables that are designed to dock with smart textiles and connect with AI to personalize protocols so that every user can get exactly what they need.


Sports / Wellness (CE) - ElectroGear Product Line

We provide physiotherapists and personal trainers with microcurrent devices, smart compression conductive garments (body sleeves, socks & shirts) and an app with an AI health coach to improve the function, the recovery & the performance of their sports & fitness clients. Note: Our wellness device is not intended to treat or prevent any injuries. In our opinion it does not require FDA certification and it would therefore not fall under the auspices of the FDA.

Next products in the pipeline: Medical - Healables Product Line

‍In Years 1-2: Treat arm, leg & back muscles, tendons, and joints to ameliorate chronic pain, accelerate healing, reduce inflammation, increase function and diminish NSAID/opioid pain med dependencies.

In addition, our medical product with specifically designed custom conductive textiles is designed to treat Diabetic neuropathy, Osteoarthritis, Fibromyalgia and Chronic lower back pain.

Note: Our first medical device will be submitted to the FDA for regulation.
5. Exciting Initial Data
88% of users showed 50% or greater pain relief that was often accompanied by the improved functional activity of the tissues affected.[7]

Healables is designed to Relieve Musculoskeletal Pain.

This graph details cases wherein our device was used to treat a variety of disorders: Musculoskeletal complaints involving the elbow, forearm, wrist, hand, knee, shoulder, or upper or lower back

Healables Reduces Inflammatory Pains.

This graph details cases wherein our device was used to treat a variety of disorders: Systemic complaints involving Fibromyalgia, Diabetic Neuropathy, Migraine, Respiratory, COPD
And we feel that’s a good reason to invest in Healables.
6. Patented Technology

We have licensed 41 patents. They were developed by Healables, Ltd.

What is the technology?
Why is the tech a good reason to invest?

Our patented tech may disrupt a broad range of verticals in multiple sectors, (ie: cosmetics, food tech, medical, veterinary, sports and wellness / fitness [7b] and automotive).

7. Market Size & Investment Opportunity
We’re striving to build the future of pain relief. Our cutting-edge wearable microcurrent technology has an opportunity to benefit from the $6.91 Billion pain management device market. [8 ][8a]
‍$6.6T: (TAM): Total Addressable Market, Long-Range Market Opportunities:

This includes Global Projections of: Wellness 6.06T [2] and Medical Device Markets 0.47T [13]
$150B (SAM): Serviceable Addressable Market, Near-Term Primary Market Focus:

Serviceable Addressable Market (SAM): $150B[18] Markets:
$1B (EVG): Serviceable Obtainable Market (SOM) & Earlyvangelists: The Big Opportunity:
While there are several companies that may be considered competitors of Healables in some form, we believe none of them on the market today delivers Healables’ combination of microcurrent, e-textiles, wearables, digital health coaching, AI and digital health telecommunications at an attractive price.
These competitors include:
8. Timing
The conditions are good for electrotherapy

Healables is a movement on a mission to restore humanity to a healthier state.

9. Validation & Partnerships
10. Current Product

We introduced our sports product called ElectroGear at CES ‘23. We are launching it in Q2 of 2023.

11. Business Model

Healables’ initial product line, ElectroGear sports performance and athletic recovery products, intended to provide an early revenue stream.

At present, Healables utilizes a hybrid B2B device/SaaS business model focusing on B2B practitioners such as physical therapists, physios, personal trainers, athletic trainers, massage therapists and other body workers.
Healables expects to generate revenue in two different ways:

Currently, the ElectroGear device is available for pre-sale. Check out to learn more


The sports performance and wellness market has enormous potential on its own[12b], yet it is less than the size of the MedTech opportunity.

The total addressable market in the MedTech space is projected to grow to $571 Billion by 2023[13]

In the MedTech category, Healables’ intended applications include treatments for:

Healables platform technology is incredibly versatile. It can be deployed across multiple verticals along a number of product lines.

Initially, we’re addressing the wellness vertical through sports performance and we’re already offering sales of ElectroGear in multiple countries.

In parallel, we’re working on fast-tracking the medical product line through the regulatory and reimbursement routes in the US, UK, and EU and are particularly interested in the DiGA legislation in Germany and Europe that reimburses digital health products that consumers can take home.

In addition to sports and medical verticals, our core technology can also be integrated into the cosmetic, veterinary and automotive verticals in the future.

12. Achieved & Upcoming Milestones

Soft-Launch, User Testing, Sports Pilot, Beta Testing, Clinical Trial


Photo: Florida Governor Ron DeSantis meeting with Oded Rose, CEO, The Israel-American Chamber of Commerce, Laura DiBella, MPE, Florida Secretary of Commerce and President & CEO of Enterprise Florida, and Shlomi Kofman, VP & Head of International Collaborations Division, Israel Innovation Authority, after signing a joint declaration to promote greater cooperation, strategic partnerships and trade and investment between Israel and Florida, with a special emphasis on the healthcare industry.

April 27, 2023, Jerusalem, Israel.
Photo credit: Israel Innovation Authority
Photo used with permission.


Updated information will be posted in this section


1 = Science Daily, 100 million Americans live with chronic pain, but treatment research is insufficient, Indiana University, Jan. 13, 2015, Science Daily,

2 = Prescient & Strategic Intelligence, Chronic Pain Treatment Market Research Report

3 = World’s Best Hospitals 2021, Newsweek,

4 = Statista, Wellness 2020 market $4.4T,

5 = The Global Burden Of Chronic Pain, Tracy P. Jackson, M.D.; Victoria Sutton Stabile, B.A.; K.A. Kelly McQueen, M.D., M.P.H. ASA Newsletter June 2014, Vol. 78, 24–27.

5a = Chronic Pain Among Adults — United States, 2019–2021, S. Michaela Rikard, PhD1; Andrea E. Strahan, PhD1; Kristine M. Schmit, MD1; Gery P. Guy Jr., PhD1, April 14, 2023, CDC,,%25%20in%202016%20(5)

6 = 31 Chronic Pain Statistics: US & Global Prevalence, LAURA SMITH, Associate Editorial Manager,

6a = Prescribing Opioids for Pain — The New CDC Clinical Practice Guideline, Deborah Dowell, M.D., M.P.H., Kathleen R. Ragan, M.S.P.H., Christopher M. Jones, Pharm.D., Dr.P.H., Grant T. Baldwin, Ph.D., M.P.H., and Roger Chou, M.D., New England Journal of Medicine (NEJM),

6b = CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022, Deborah Dowell, M.D., M.P.H., Kathleen R. Ragan, M.S.P.H., Christopher M. Jones, Pharm.D., Dr.P.H., Grant T. Baldwin, Ph.D., M.P.H., and Roger Chou, M.D., National Institutes of Health (NIH), National Library of Medicine, National Center for Biotechnology Information,

6c = NOPAIN Act, Voices For Non Opioid Choices,

6d = New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults, National Institutes of Health (NIH), National Library of Medicine, National Center for Biotechnology Information,

6e = Overdose Deaths Accelerating During COVID-19, Center for Disease Control and Prevention,

7 = Healables compendium, Dr. Shiller, Dr. Ehrenberg, Dr. Lowell, Healables internal data

7b = The Six Reasons The Fitness Industry Is Booming, Forbes,

8 = Pain Management Devices Market, Grand View Research,

8a – Pain Management Devices Market Size, Share & Trends Analysis Report By Product (RFA, Neurostimulation), By Application (Neuropathic Pain, Cancer), By Region (APAC, North America), And Segment Forecasts, 2022 – 2030,

9 = Statista, Wellness and Spa,

10= S.586 – NOPAIN Act, Sponsor: Sen. Capito, Shelley Moore [R-WV] (Introduced 03/04/2021),

11 = H.R.3259 – NOPAIN Act, Sponsor: Rep. Sewell, Terri A. [D-AL-7] (Introduced 05/14/2021),


12b = Sports Medicine Market Size to Reach USD 10270 Million by 2027 at a CAGR of 7.5% | Valuates Reports PR Newswire,–valuates-reports-301388619.html

13 = Statista, Medical Technology,

14 = Health and Economic Costs of Chronic Diseases, National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), CDC, March 23, 2023,

15 = Pain Management Devices Market Size, Share & Trends Analysis Report By Product (RFA, Neurostimulation), By Application (Neuropathic Pain, Cancer), By Region (APAC, North America), And Segment Forecasts, 2022 – 2030,

16 = Physiotherapy Equipment Market Size, Share & Trends Analysis Report By Application (Neurology, Musculoskeletal, Pediatrics), By Type, By Demographics, By End Use, By Region, And Segment Forecasts, 2023 – 2030, Grand View Research, Report ID: 978-1-68038-476-5,

17 = Emergence Research: “The global pain relief market size was USD $79.68B in 2021 and is expected to register a revenue CAGR of 4.5% during the forecast period” so that in 2023 the projected market size is USD $87B.,4.5%25%20during%20the%20forecast%20period

18 = Personal Fitness Trainer Market Outlook (2022 to 2032), Future Market Insights,

19 = Medical Devices Market Size, Fortune Business Insights,

20 = Pain Medicine, South Rampart Pharma, 2022, “Significant Unmet Need & Market Opportunity”

21 = Pain Management Therapeutics Market (By Drug Class: NSAIDs, Opioids, Anesthetics, Antidepressants, Anticonvulsants, and Others; By Indication: Arthritic Pain, Neuropathic Pain, Chronic Back Pain, Post-Operative Pain, Cancer Pain, and Others; By Distribution Channel: Online Pharmacy, Retail Pharmacy, and Hospital Pharmacy) – Global Industry Analysis, Market Size, Share, Growth, Trends, Regional Outlook and Forecasts, 2022 – 2030, Precedence Research: The global pain management therapeutics market was valued at USD 72.41 billion in 2021 and is predicted to hit over USD 105.77 billion by 2030, expanding growth at a CAGR of 4.3% during the forecast period 2022 to 2030.

22 = Citation that the CE mark is globally considered the gold standard:’s%20CE%20marking%20is,and%20safety%20norms%20and%20laws.

23 = The diabetic neuropathy market was valued at $3.9B in 2022, and is projected to be $6.6B in 2030.

24 = The global market for Osteoarthritis Therapeutics estimated at US$7.9 Billion in the year 2022, is projected to reach a revised size of US$15.8 Billion by 2030, growing at a CAGR of 9.1% over the period 2022-2030. Knee, one of the segments analyzed in the report, is projected to record 10.1% CAGR and reach US$7.1 Billion by the end of the analysis period.

25 = Fibromyalgia Treatment Market Research | 2023-2030, June 13, 2023, MarketWatch,

26 = Global Chronic Lower Back Pain Treatment Market Report 2023: Increasing Government Initiatives, An Aging Population, and Growing Awareness About Pain Management Drive 4.9% Annual Growth, April 25, 2023, Source: Research and Markets,

Why invest in startups?

Crowdfunding is designed to allow investors to support startups and early-growth companies that they are passionate about. This is different from helping a company raise money on Kickstarter. With Regulation CF Offerings, you aren’t buying products or merch. You are buying a piece of a company and helping it grow.

What types of securities can I buy on Healables?

The majority of offerings are common stock, though some companies may raise capital through convertible note, debt, and revenue share.

How much can I invest?

Investors other than accredited investors are limited in the amounts they are allowed to invest in all Regulation Crowdfunding offerings (on this site and elsewhere) over the course of a 12-month period: If either of an investor’s annual income or net worth is less than $124,000, then the investor’s investment limit $2,500, or 5 percent of the greater of the investor’s annual income or net worth, whichever is greater. If both an investor’s annual income and net worth are $124,000 or higher, then the investor’s limit is 10 percent of the greater of their annual income or net worth, or $124,000 whichever is greater. Accredited investors are not limited in the amount they can invest.

How do I calculate my net worth?

Calculating net worth involves adding up all your assets and subtracting all your liabilities. The resulting sum is your net worth.

What are the tax implications of an equity crowdfunding investment?

We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.

Who can invest in a Regulation CF Offering?

Individuals over 18 years of age can invest. Currently however, Canadian citizens are not able to invest in Regulation CF offerings.

What do I need to know about early-stage investing? Are these investments risky?

Ref CF Offerings are high risk opportunities and may not retain their value. Investing in startups and small businesses is inherently risky and standard company risk factors such as execution and strategy risk are often magnified at the early stages of a company. In the event that a company goes out of business, your ownership interest could lose all value. Furthermore, private investments in startup companies are illiquid instruments that typically take up to five and seven years (if ever) before an exit via acquisition, IPO, etc.

When will I get my investment back?

Companies conducting a Reg CF are privately held companies, and their shares are not traded on a public stock exchange. As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically receive a return on your investment under the following two scenarios: The company gets acquired by another company. The company goes public (makes an initial public offering on the NASDAQ, NYSE, or another exchange). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on the exchange. It can take 5-7 years (or longer) to see a distribution or trading, as it takes years to build companies. In many cases, there will not be any return as a result of business failure. Dalmore Group, LLC does not make investment recommendations, and no communication, through this website or in any other medium should be construed as a recommendation for any security offered on or off this investment platform. Investments in private placements and start-up investments in particular are speculative and involve a high degree of risk, and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investments tend to be in earlier stages of development, and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Additionally, investors on Regulation CF offerings will receive securities that are subject to holding period requirements. The most sensible investment strategy for start-up investing may include a balanced portfolio of different start-ups. Start-ups should only be part of your overall investment portfolio. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest.

Can I sell my shares?

Shares sold via Regulation Crowdfunding offerings have a one-year lock up period before those shares can be sold freely. Exceptions to limitations on selling shares during the one-year lock up are transfers:

  • -to the company that issued the securities;
  • -to an accredited investor;
  • -to a family member (defined as a child, stepchild, grandchild, parent, -stepparent, grandparent, spouse or spousal equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships.);
  • -in connection with your death or divorce or other similar circumstance;


What information does Healables collect from issuers related to their offering?

The organization of the company Dalmore Group, LLC requires information that shows the issuer company has taken steps necessary to organize as a corporation or LLC in its state of organization, is in good standing, and that the securities being issued will be duly authorized and validly issued. The corporate structure and ownership Dalmore Group, LLC works with the issuer company to disclose its organizational structure, affiliated entities, and current capitalization. The people behind the company Dalmore Group, LLC helps the issuer company disclose who is behind the operations and strategy of the company, along with their previous related experience, and Bad Actor Reports to provide evidence that the company is not disqualified from proceeding with its offering.  Information provided to investors Dalmore Group, LLC checks that the issuer company is providing clear disclosure of its financial situation, business origins, and operations, and legal authority to engage in its business activities. Investor information and terms of the offering Dalmore Group, LLC reviews for consistency each instance where the issuer company describes the offering terms, and identifies to investors how the issuer company reached its current valuation and will track and keep in touch with its security holders. Review of transaction documents Dalmore Group, LLC performs an independent review of transaction documents to check for red flags & conformance with stated terms.  Business due diligence Dalmore Group, LLC conducts research and due diligence on each company before it is able to accept investments on the platform.  Dalmore Group, LLC will typically conduct over 30-40 hours of due diligence per opportunity, which requires the satisfactory completion of a detailed set of individual questions and data requests.  Particular focus is paid to the following issues throughout the due diligence process:  Problem or inefficiency being addressed Product / service overview, stage of development and anticipated milestones Demonstrated traction (e.g. revenue, pre-sales, purchase orders, signed contracts, media coverage, awards, etc.) Data to support claims made in marketing materials (e.g. user / customer metrics, signed contracts and agreements, product demonstrations, etc.) Growth strategy Employees and advisors (including ownership structure) Addressable market (e.g. size, growth, penetration, etc.) Competitive landscape and industry dynamics Exit opportunities Intellectual property Historical financials Financial projections (including error-checking, evaluation of key assumptions and reconciliation to stated growth plan) Reference checks (e.g. previous investors, advisors, etc.) Investment overview (including determination of key terms, uses of funds, and current and previous investors) The findings of the foregoing review are presented to Dalmore Group, LLC, which may approve, reject, or require additional information for the offering. Upon approval and following the onboarding process, an offering can begin accepting investments online. General considerations Notwithstanding the foregoing, these investments are illiquid, risky and speculative and you may lose your entire investment.  The foregoing summarizes our standard process. However, each diligence review is tailored to the nature of the company, so the aforementioned process is not the same for every issuer. Completing the vetting process does NOT guarantee that the company has no outstanding issues or that problems will not arise in the future.  While the foregoing process is designed to identify material issues, there is no guarantee that there will not be errors, omissions, or oversights in the due diligence process or in the work of third-party vendors utilized by Dalmore Group, LLC. Each investor must conduct their own independent review of documentation and perform their own independent due diligence and should ask for any further information required to make an investment decision.

What happens if a company does not reach their funding goal?

If a company does not reach their minimum funding goal, all funds will be returned to the investors after the closing of their offering.

How can I learn more about a company’s offering?

All available financial information can be found on the offering pages for the company’s Regulation Crowdfunding offering.

What if I change my mind about investing?

You may cancel your investment at any time, for any reason until 48 hours prior to a closing occurring.  If you have already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation.  To submit a request to cancel your investment please email:

How do I contact someone at Healables?

If you have questions that have not been answered in the FAQ, please email our Investor Support Team at:


One thought on “Invest”

Add a Comment

Your email address will not be published.

Get Updates



Raised from 15 investments

(Min. $250)

Pre-Market Valuation: $29.27M

If you invest, you’re betting Healables will be worth more in the future.

Dr. George Lowell, Retired U.S. Army Colonel, BioTech Investor, Board Member, BiondVax, Former Chief Scientific Officer for BioDefense at GSK Biologicals, Early Seed Investor in Healables
“We have taken on a vital mission, to achieve faster healing and pain relief for people suffering from chronic pain. It’s a great feeling to know your product helps people. Join me today, and become a Healables investor, so that together, we can build a future without pain.”
Invested this round & previously
TOTAL RAISED Pre-CrowdFunding:
$1.2 Million